Published in J Urol on January 15, 2011
Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. J Clin Oncol (2015) 5.00
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer (2013) 1.75
Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology (2012) 1.54
Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis (2013) 1.48
Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. Urology (2013) 1.47
Application of metabolomics to prostate cancer. Urol Oncol (2011) 1.28
Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. Eur Urol (2014) 1.21
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
Impact of surgical margin status on prostate-cancer-specific mortality. BJU Int (2012) 1.13
Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res (2012) 1.12
Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. Curr Oncol (2012) 1.03
Application of the 2013 American Urological Association early detection of prostate cancer guideline: who will we miss? World J Urol (2014) 1.02
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A (2012) 1.00
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Biochemical recurrence in Gleason score 7 prostate cancer in korean men: significance of the primary Gleason grade. Korean J Urol (2012) 0.95
Automatic classification of prostate cancer Gleason scores from multiparametric magnetic resonance images. Proc Natl Acad Sci U S A (2015) 0.93
Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol (2014) 0.92
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Prediction of prostate cancer recurrence using quantitative phase imaging. Sci Rep (2015) 0.92
A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT). Contemp Clin Trials (2014) 0.90
Low-grade prostate cancer diverges early from high grade and metastatic disease. Cancer Sci (2014) 0.90
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate (2015) 0.90
PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer. Br J Med Surg Urol (2012) 0.89
5-α reductase inhibitors and prostate cancer prevention: where do we turn now? BMC Med (2011) 0.89
The role of radical prostatectomy in high-risk prostate cancer. Prostate Int (2013) 0.89
Chemoprevention of prostate cancer: an updated view. World J Urol (2012) 0.89
Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol (2014) 0.88
Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy. Hum Pathol (2012) 0.88
Histological outcomes after focal high-intensity focused ultrasound and cryotherapy. World J Urol (2015) 0.86
MicroRNAs as putative mediators of treatment response in prostate cancer. Nat Rev Urol (2012) 0.86
Management of low (favourable)-risk prostate cancer. BJU Int (2011) 0.84
The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. Clin Cancer Res (2014) 0.84
The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance. Prostate Int (2014) 0.84
Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up. Prostate Cancer Prostatic Dis (2016) 0.82
Active surveillance and focal therapy for low-intermediate risk prostate cancer. Transl Androl Urol (2015) 0.82
Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res (2015) 0.82
Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. Int J Radiat Oncol Biol Phys (2015) 0.81
Clinically available RNA profiling tests of prostate tumors: utility and comparison. Asian J Androl (2016) 0.81
The role of germline mutations in the BRCA1/2 and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer. Fam Cancer (2016) 0.81
Current clinical challenges in prostate cancer. Transl Androl Urol (2013) 0.81
Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer. Asian J Androl (2016) 0.80
Patient selection essential in optimizing the benefit of radical prostatectomy for patients with organ-confined prostate cancer. Asian J Androl (2011) 0.80
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs (2013) 0.80
Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun (2016) 0.80
The association between race and treatment regret among men with recurrent prostate cancer. Prostate Cancer Prostatic Dis (2014) 0.79
Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer. World J Urol (2013) 0.79
Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection. World J Surg Oncol (2012) 0.79
Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. PLoS One (2015) 0.79
Should Gleason 6 be labeled as cancer? Curr Opin Urol (2015) 0.78
The role for surgery in high-risk prostate cancer. Wien Med Wochenschr (2015) 0.78
Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer? Yonsei Med J (2015) 0.78
Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness? J Cancer Res Clin Oncol (2015) 0.77
Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms-A whole of population study. Prostate Int (2015) 0.77
Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. Eur Urol (2015) 0.77
A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy. PLoS Curr (2015) 0.77
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. World J Urol (2015) 0.77
Oncologic outcomes of patients with Gleason score 7 and tertiary Gleason pattern 5 after radical prostatectomy. Korean J Urol (2013) 0.77
Prostate biopsy perineural invasion is not independently associated with positive surgical margins following radical retropubic prostatectomy. World J Urol (2014) 0.77
Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer. Oncotarget (2016) 0.76
The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol (2015) 0.76
Does true Gleason pattern 3 merit its cancer descriptor? Nat Rev Urol (2016) 0.76
Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol (2013) 0.76
Is Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer? J Korean Med Sci (2015) 0.75
Clinical management and burden of prostate cancer: a Markov Monte Carlo model. PLoS One (2014) 0.75
Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with (18)F-fluorocholine positron emission tomography/computed tomography. World J Urol (2015) 0.75
Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia. Can Urol Assoc J (2015) 0.75
Contemporary Role of the Decipher® Test in Prostate Cancer Management: Current Practice and Future Perspectives. Rev Urol (2016) 0.75
Is pathology necessary to predict mortality among men with prostate-cancer? BMC Med Inform Decis Mak (2014) 0.75
Clinical significance of surgical margin status in patients subjected to radical prostatectomy. Cent European J Urol (2012) 0.75
Deriving benefit of early detection from biomarker-based prognostic models. Biostatistics (2012) 0.75
Radical prostatectomy is the most cost-effective primary treatment modality for men diagnosed with high-risk prostate cancer. Can Urol Assoc J (2012) 0.75
Interpretation of PIVOT findings. Transl Androl Urol (2012) 0.75
PREDICT: model for prediction of survival in localized prostate cancer. World J Urol (2015) 0.75
Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer. Int J Clin Exp Pathol (2014) 0.75
Does the presence of hypoechoic lesions on transrectal ultrasound suggest a poor prognosis for patients with localized prostate cancer? Korean J Urol (2013) 0.75
Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer. Cancer Med (2016) 0.75
[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report. BMC Urol (2016) 0.75
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer. Oncologist (2015) 0.75
Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes. Int Braz J Urol (2016) 0.75
Clinical value of core length in contemporary multicore prostate biopsy. PLoS One (2015) 0.75
Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. Sci Rep (2016) 0.75
Robot-assisted radical prostatectomy in low- and high-risk prostate cancer patients. Turk J Urol (2017) 0.75
Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis (2016) 0.75
Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation. Oncotarget (2016) 0.75
The effect of Rapid Access Prostate Clinics on the outcomes of Gleason 7 prostate cancer: does earlier diagnosis lead to better outcomes? Ir J Med Sci (2017) 0.75
Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. Prostate Cancer Prostatic Dis (2017) 0.75
Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol (2017) 0.75
Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World J Urol (2014) 0.75
A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol (2016) 0.75
Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol (2016) 0.75
Correlation between postoperative prostate-specific antigen and biochemical recurrence in positive surgical margin patients: Single surgeon series. Prostate Int (2017) 0.75
Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. Radiology (2017) 0.75
Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World J Urol (2016) 0.75
Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clin Cancer Res (2017) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Evaluating the yield of medical tests. JAMA (1982) 14.05
The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol (2005) 12.31
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol (2007) 6.23
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med (1999) 6.21
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol (2005) 2.05
25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol (2006) 1.82
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol (2006) 8.61
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol (2003) 5.20
Variations in lung cancer risk among smokers. J Natl Cancer Inst (2003) 5.00
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst (2006) 4.14
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol (2002) 3.93
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol (2010) 3.76
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol (2009) 3.74
Against diagnosis. Ann Intern Med (2008) 3.69
Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol (2013) 3.65